Cargando…
The use of oncolytic virotherapy in the neoadjuvant setting
Surgical removal of tumors remains a front-line therapy for many types of cancer. However, this treatment often fails to eradicate disease due to either recurrence of the original tumor or development of distant micrometastases. To address these challenges, patients are often given non-curative trea...
Autores principales: | Thomas, Raquela J, Bartee, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006794/ https://www.ncbi.nlm.nih.gov/pubmed/35414592 http://dx.doi.org/10.1136/jitc-2021-004462 |
Ejemplares similares
-
Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019) -
Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012) -
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022) -
Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
por: Thomas, Raquela J., et al.
Publicado: (2023) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)